|
FR2724320B1
(fr)
|
1994-09-13 |
1996-12-20 |
Transgene Sa |
Nouvel implant pour le traitement des maladies acquises
|
|
CN1201005C
(zh)
|
1996-05-22 |
2005-05-11 |
维文蒂阿生物技术股份有限公司 |
特异性检测癌细胞的抗原结合片段、编码所述片段的dna、以及它们在预防和检测癌症上的用途
|
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
|
US20030095967A1
(en)
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
|
PL211786B1
(pl)
|
1999-08-17 |
2012-06-29 |
Apoxis Sa |
Zastosowanie przeciwciała oraz polipeptydu
|
|
DE60128216T2
(de)
|
2000-05-12 |
2008-01-10 |
Amgen Inc., Thousand Oaks |
Polypeptide zum Hemmen der April-vermittelten Proliferation von B- und T- Zellen
|
|
CA2438682A1
(en)
|
2001-02-20 |
2002-08-29 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
JP2003111595A
(ja)
|
2001-06-25 |
2003-04-15 |
Kyogo Ito |
腫瘍抗原
|
|
US20080267965A1
(en)
|
2002-02-21 |
2008-10-30 |
Kalled Susan L |
Use of Bcma as an Immunoregulatory Agent
|
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
|
DK1629011T3
(da)
|
2003-05-31 |
2010-05-03 |
Micromet Ag |
Humane anti-humane-DC3-bindingsmolekyler
|
|
ZA200601699B
(en)
|
2003-10-16 |
2007-05-30 |
Micromet Ag |
Multispecific deimmunized CD3-binders
|
|
RU2006117324A
(ru)
|
2003-10-20 |
2007-12-10 |
Байоджен Айдек Ма Инк. (Us) |
Терапевтические режимы для антагонистов baff
|
|
US7947805B2
(en)
|
2004-12-23 |
2011-05-24 |
Merck Serono S.A. |
BCMA polypeptides and uses thereof
|
|
HUE025945T2
(en)
|
2005-02-15 |
2016-07-28 |
Univ Duke |
Anti-CD19 antibodies and their applications in oncology
|
|
JP2009521474A
(ja)
|
2005-12-21 |
2009-06-04 |
メディミューン，エルエルシー |
ＥｐｈＡ２ＢｉＴＥ分子およびその使用
|
|
MX2008015771A
(es)
|
2006-06-14 |
2009-01-27 |
Macrogenics Inc |
Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
|
|
CN101679966B
(zh)
|
2007-01-24 |
2014-03-12 |
协和发酵麒麟株式会社 |
具有增强的效应子活性的遗传重组抗体组合物
|
|
CA2681728C
(en)
|
2007-03-27 |
2015-12-22 |
Zymogenetics, Inc. |
Combination of blys and/or april inhibition and immunnosuppressants for treatment of autoimmune disease
|
|
US8460647B2
(en)
|
2007-04-20 |
2013-06-11 |
Amgen Inc. |
Pre-ligand assembly domain of the IL-17 receptor
|
|
SG194399A1
(en)
|
2008-10-01 |
2013-11-29 |
Amgen Res Munich Gmbh |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
|
|
WO2010081173A2
(en)
|
2009-01-12 |
2010-07-15 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
|
KR101589785B1
(ko)
|
2009-03-10 |
2016-01-28 |
바이오젠 엠에이 인코포레이티드 |
항-ｂｃｍａ 항체
|
|
US9273283B2
(en)
*
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
US9169328B2
(en)
|
2010-03-26 |
2015-10-27 |
Memorial Sloan Kettering Cancer Center |
Antibodies to MUC16 and methods of use thereof
|
|
EP2611834B1
(en)
|
2010-09-01 |
2018-03-07 |
Biogen MA Inc. |
Rapid generation of anti-idiotypic antibodies
|
|
US20130273055A1
(en)
|
2010-11-16 |
2013-10-17 |
Eric Borges |
Agents and methods for treating diseases that correlate with bcma expression
|
|
WO2012106587A1
(en)
|
2011-02-04 |
2012-08-09 |
Genentech, Inc. |
Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
|
|
US20120213768A1
(en)
|
2011-02-19 |
2012-08-23 |
Baylor Research Institute |
Diagnostic and Therapeutic Uses for B Cell Maturation Antigen
|
|
TWI838039B
(zh)
|
2011-03-28 |
2024-04-01 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
US20130101599A1
(en)
|
2011-04-21 |
2013-04-25 |
Boehringer Ingelheim International Gmbh |
Bcma-based stratification and therapy for multiple myeloma patients
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
SI3415531T1
(sl)
|
2011-05-27 |
2023-12-29 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) - vezni proteini
|
|
WO2013059885A2
(en)
|
2011-10-28 |
2013-05-02 |
Cephalon Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
JP6441079B2
(ja)
|
2011-12-19 |
2018-12-19 |
シンイミューン ゲーエムベーハー |
二重特異性抗体分子
|
|
EP3594245A1
(en)
|
2012-02-13 |
2020-01-15 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
WO2013132268A1
(en)
|
2012-03-09 |
2013-09-12 |
Ucl Business Plc |
Chemical modification of antibodies
|
|
AU2013289971A1
(en)
|
2012-07-13 |
2015-01-22 |
The Trustees Of The University Of Pennsylvania |
Enhancing activity of CAR T cells by co-introducing a bispecific antibody
|
|
US9963513B2
(en)
|
2013-02-05 |
2018-05-08 |
Engmab Sàrl |
Method for the selection of antibodies against BCMA
|
|
CN105531374A
(zh)
|
2013-07-12 |
2016-04-27 |
酵活有限公司 |
双特异性cd3和cd19抗原结合构建体
|
|
CN105848484A
(zh)
|
2013-10-25 |
2016-08-10 |
得克萨斯州大学系统董事会 |
用于免疫治疗的多克隆γδ T细胞
|
|
CN106459990B
(zh)
|
2014-02-07 |
2021-06-01 |
麦克马斯特大学 |
三功能t细胞抗原偶联物及其制备方法和用途
|
|
EP3593812A3
(en)
*
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
WO2016166139A1
(en)
*
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
|
US11059880B2
(en)
*
|
2015-06-30 |
2021-07-13 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
US20210206826A1
(en)
|
2015-11-19 |
2021-07-08 |
The Regents Of The University Of California |
Conditionally repressible immune cell receptors and methods of use thereof
|
|
US10822408B2
(en)
|
2015-12-15 |
2020-11-03 |
Amgen Inc. |
PACAP antibodies and uses thereof
|
|
CA3032838A1
(en)
|
2016-08-04 |
2018-02-08 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
CN108250302A
(zh)
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多功能蛋白质
|
|
JP7227630B2
(ja)
|
2017-10-12 |
2023-02-22 |
マックマスター ユニバーシティー |
Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
|
|
AU2019307905B2
(en)
|
2018-07-17 |
2024-09-12 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
CN113490689B
(zh)
|
2019-02-01 |
2024-06-04 |
恺兴生命科技(上海)有限公司 |
Tcr融合蛋白及表达tcr融合蛋白的细胞
|
|
WO2022099076A1
(en)
|
2020-11-06 |
2022-05-12 |
Mcmaster University |
Cells comprising t cell-antigen couplers and uses thereof
|
|
EP4347660A4
(en)
|
2021-06-01 |
2025-06-04 |
Triumvira Immunologics USA, Inc. |
CLAUDIN-18.2 T-CELL ANTIGEN COUPLER AND USES THEREOF
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|